Hello J8,
"My view, they have not dosed patient 7 or 8 yet"
I think you are exactly right. If there first three sites were doing well, then why open a fourth? I suspect that suitable candidates are in short supply and a difficulty in getting patients for trials contributed to the haste to complete the last capital raising. News about effacy seems to drift futher into the distant future. Please Peter, under promise and over deliver; not the other way round.
- Forums
- ASX - By Stock
- BLT
- Ann: FOURTH SITE IN HEPATITIS C CLINICAL TRIAL
Ann: FOURTH SITE IN HEPATITIS C CLINICAL TRIAL, page-3
-
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online